论文部分内容阅读
目的:评价盐酸坦索罗辛(tamsulosin)在治疗合并BPH的输尿管下段结石患者中的临床疗效。方法:将50例合并BPH的输尿管下段结石患者随机分成两组,每组25例,结石直径小于1.0 cm。对照组患者未给予输尿管平滑肌松弛剂;坦索罗辛组患者加用坦索罗辛0.2 mg,每天1次。每例患者治疗观察期不超过2周。观察结石排出率、结石排出时间、肾绞痛及副作用发生率、镇痛治疗使用率及其它疗法介入率。结果:坦索罗辛组结石排出率均显著高于对照组,结石排出时间、肾绞痛发生率和哌替啶的使用率也均显著低于对照组(P<0.05)。对照组选用其他疗法介入率显著高于坦索罗辛组(P<0.05)。对照组尿潴留发生率明显高于坦索罗辛组(P<0.05)。两组患者均未观察到明显的药物副作用(P>0.05)。结论:坦索罗辛可明显促进输尿管下段结石排出,缓解肾绞痛发生同时改善排尿症状,可作为一种有效的输尿管下段结石辅助药物疗法。
OBJECTIVE: To evaluate the clinical efficacy of tamsulosin in the treatment of patients with lower ureteral calculi associated with BPH. Methods: Fifty patients with lower ureteral calculi combined with BPH were randomly divided into two groups, 25 cases in each group. The diameter of stones was less than 1.0 cm. Patients in the control group were not given ureteral smooth muscle relaxants; patients in tamsulosin group were given tamsulosin 0.2 mg once daily. Each patient treatment observation period of no more than 2 weeks. Observe the stone discharge rate, stone discharge time, incidence of renal colic and side effects, analgesic treatment and other intervention rates. Results: The tamsulosin group was significantly higher than the control group stone discharge rate, stone discharge time, incidence of renal colic and pethidine were also significantly lower than the control group (P <0.05). The intervention rate of other therapy in the control group was significantly higher than tamsulosin group (P <0.05). The incidence of urinary retention in the control group was significantly higher than that in the tamsulosin group (P <0.05). No obvious adverse drug side effects were observed in both groups (P> 0.05). Conclusion: Tamsulosin can significantly promote the lower ureteral stones to relieve the occurrence of renal colic and improve the symptoms of urination, can be used as an effective lower ureteral calculi adjuvant drug therapy.